@article {Arnoldjrheum.100365, author = {Lesley M. Arnold and Daniel Clauw and Fujun Wang and Jonna Ahl and Paula J. Gaynor and Madelaine M. Wohlreich}, title = {Flexible Dosed Duloxetine in the Treatment of Fibromyalgia: A Randomized, Double-blind, Placebo-controlled Trial}, elocation-id = {jrheum.100365}, year = {2010}, doi = {10.3899/jrheum.100365}, publisher = {The Journal of Rheumatology}, abstract = {Objective To investigate the efficacy of flexible dose duloxetine 60{\textendash}120 mg/day on changes in fibromyalgia (FM) symptoms assessed by the Patient Global Impression of Improvement (PGI-I) scale. Methods Outpatients >= 18 years of age who met American College of Rheumatology criteria for FM, and had >= 4 score on the Brief Pain Inventory (BPI) average pain item, were randomized to duloxetine (n = 263) or placebo (n = 267) for 24 week double-blind treatment (primary endpoint at Week 12). Key secondary measures included BPI average pain severity, patient-rated scales assessing mood, anxiety, pain, sleep, and stiffness, Clinical Global Impression of Severity (CGI-S), Multidimensional Fatigue Inventory, Cognitive and Physical Functioning Questionnaire, Beck Depression Inventory (BDI), Beck Anxiety Inventory, and Medical Outcome Study Short-Form Health Survey (SF-36). Results At Week 12, duloxetine-treated patients reported significantly greater global improvement with mean PGI-I scores of 2.8 compared to 3.4 in the placebo group (p \< 0.001). Significantly more duloxetine-versus placebo-treated patients (57\% vs 32\%; p \< 0.001) reported feeling {\textquotedblleft}much{\textquotedblright} or {\textquotedblleft}very much better{\textquotedblright} (PGI-I score <= 2). There was significantly greater improvement with duloxetine versus placebo treatment in BPI average pain severity, mood (including BDI total), anxiety (patient-rated only), stiffness, CGI-S, fatigue, all SF-36 domains (except role-physical and physical component summary), and being less bothered by pain or sleep difficulties. Treatment-emergent adverse events occurring significantly more frequently with duloxetine included: nausea, headache, constipation, dry mouth, dizziness, diarrhea, and hyperhidrosis. Conclusion Treatment with duloxetine 60, 90, and 120 mg/day was associated with feeling much better, pain reduction, being less bothered by sleep difficulties, and improvement in mood, stiffness, fatigue and functioning. (Clinical trial registry NCT00673452).}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/early/2010/09/09/jrheum.100365}, eprint = {https://www.jrheum.org/content/early/2010/09/09/jrheum.100365.full.pdf}, journal = {The Journal of Rheumatology} }